Cullinan Therapeutics
CGEM
113 hedge funds and large institutions have $376M invested in Cullinan Therapeutics in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 24 reducing their positions, and 14 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 24
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
50% more capital inflows, than outflows
Capital inflows: $60.3M | Capital outflows: $40.2M
7% more funds holding
Funds holding: 106 → 113 (+7)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.77% less ownership
Funds ownership: 88.93% → 86.16% (-2.8%)
12% less call options, than puts
Call options by funds: $97K | Put options by funds: $110K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blue Owl Capital Holdings
New York
|
+$30.3M |
| 2 |
Morgan Stanley
New York
|
+$5.64M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.79M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$3.46M |
| 5 |
Affinity Asset Advisors
New York
|
+$2.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.4M |
| 2 |
Boxer Capital
San Diego,
California
|
-$9.7M |
| 3 |
Braidwell
Stamford,
Connecticut
|
-$5.92M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$5.51M |
| 5 |
Kennedy Capital Management
St Louis,
Missouri
|
-$2.92M |
CGEM Hedge Fund Activity: Q4 2023 in Review
113 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Cullinan Therapeutics (CGEM) for Q4 2023, worth a combined $376M — up 9.2% from $344M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CGEM positions and 14 closed out — a net gain of 9 holders — while 45 added to existing stakes and 24 trimmed.
The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $30.3M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $10.4M sold.
- 113 institutional investors held Cullinan Therapeutics (CGEM) as of Q4 2023, up from 106 in Q3 2023.
- Funds reported $376M of Cullinan Therapeutics stock for Q4 2023, up 9.2% quarter-over-quarter.
- 23 funds opened new Cullinan Therapeutics positions in Q4 2023 and 14 closed out, a net change of +9 holders.
- The largest Cullinan Therapeutics buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $30.3M added.
- The largest Cullinan Therapeutics seller in Q4 2023 was Adage Capital Partners, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2023.